Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024

Rhea-AI Summary

Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, will release its financial results for Q2 2024 on August 8, 2024, after the market closes. A conference call will follow at 4:30 p.m. ET, accessible via the Investor Relations section of the company's website or by phone. Insulet's flagship product, the Omnipod® platform, offers innovative insulin delivery solutions, including the Omnipod 5 Automated Insulin Delivery System, which integrates with continuous glucose monitors for simplified diabetes management.

Positive

• Insulet is set to release its Q2 2024 financial results, providing transparency and potentially positive insights into the company's performance.

Negative

• None.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2024 on August 8, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240708503037/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

When will Insulet announce its Q2 2024 financial results?

Insulet will announce its Q2 2024 financial results on August 8, 2024, after the market closes.

What is the stock symbol for Insulet ?

The stock symbol for Insulet is PODD.

How can I access the conference call for Insulet's Q2 2024 financial results?

The conference call can be accessed via the Investor Relations section of Insulet's website or by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, with the passcode 5904836.

What product does Insulet specialize in?

Insulet specializes in the Omnipod® platform, a tubeless insulin pump technology.

What is the Omnipod 5 Automated Insulin Delivery System?

The Omnipod 5 Automated Insulin Delivery System is an advanced insulin delivery system that integrates with continuous glucose monitors to manage blood sugar levels without multiple daily injections or fingersticks.